TITLE:
Effects of Darbepoetin-α on Oxidative Stress Marker in Patients with Chronic Renal Failure
AUTHORS:
Norio Nakamura, Michiko Shimada, Ikuyo Narita, Yuko Shimaya, Takeshi Fujita, Reiichi Murakami, Hiroshi Osawa, Hideaki Yamabe, Ken Okumura
KEYWORDS:
Chronic Renal Failure; Darbepoetin-α; Epoetin-α; Indoxyl Sulfate; MDA-LDL; Renal Anemia
JOURNAL NAME:
Open Journal of Nephrology,
Vol.4 No.1,
March
7,
2014
ABSTRACT: Objective: Long-acting darbepoetin-α (DA)
has recently been used to treat renal anemia in patients with chronic renal
failure. It is considered clinically useful because its duration of action is
longer than that of conventional epoetin-α.
In this study, we investigated changes in the levels of the oxidative stress
marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal
anemia, and renal function when patients were treated for chronic renal failure switched from epoetin-α to DA. Materials and Methods: The subjects included
nine patients with chronic renal failure and renal anemia who were treated with epoetin-α on an outpatient basis at our department. Blood was sampled prior to the
switch and at 3, 6, and 12 months after the switch. We then investigated
changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels. Results: There were no significant
changes in MDA-LDL and Hb levels after switching to DA. A significant increase
was observed in Cr levels after 12
months compared with those prior to switching. Conclusion: Once-a-month administration of DA did not result in an increase in oxidative
stress, and therefore, DA is considered capable of controlling renal anemia.